We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 13, 2020

Pixantrone + Rituximab vs Gemcitabine + Rituximab in Relapsed Aggressive B‐Cell NHL Ineligible for Transplant

British Journal of Haematology

 

Additional Info

British Journal of Haematology
Pixantrone Plus Rituximab Versus Gemcitabine Plus Rituximab in Patients With Relapsed Aggressive B‐Cell Non‐Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation: A Phase 3, Randomized, Multicentre Trial (PIX306)
Br. J. Haematol 2019 Dec 27;[EPub Ahead of Print], R Pettengell, M Długosz‐Danecka, D Andorsky, D Belada, P Georgiev, D Quick, JW Singer, SB Singh, A Pallis, A Egorov, G Salles

Further Reading